Hang Chen

VP of Research

Dr. Chen is the VP of Research at BridGene Biosciences, Inc. He has 18+ years’s drug discovery & development experience in small molecule drugs and biologic drugs at both large bio-pharmaceutical and start-up companies . He has expertise in different areas of innate immune function, neurological disorders, PET-tracer discovery, and tumor imaging.

Dr. Chen has led various drug discovery and research teams in NexStar, Renovis, Amgen, and Denali Therapeutics. Those projects included small molecule inhibitors for GPCR, transporters, intracellular enzymes and antibodies against immune receptors. At Amgen, Dr. Chen initiated and led the target occupancy technology platform. He and his colleagues discovered and developed a novel small molecules PET-tracer to address the critical problems of target engagement and dosage selection of the therapeutics in clinic.

Dr. Chen received his Ph.D. from University of Colorado at Boulder in Biochemistry and did his Postdoctoral fellowship at University of California San Francisco. He has published many research papers in high profile journals